Eiger BioPharmaceuticals, Inc. (EIGR)


Stock Price Forecast

April 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Eiger BioPharmaceuticals, Inc. chart...

About the Company

We do not have any company description for Eiger BioPharmaceuticals, Inc. at the moment.

Exchange

Nasdaq

$10M

Total Revenue

2

Employees

$3M

Market Capitalization

-0.25

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $EIGR News

Requiem for Eiger Biopharmaceuticals

Opinion ago, source:

After 24 years in business, the drug innovator hit the FDA’s approval roadblock.

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

18d ago, source:

Announces “Stalking Horse” Agreement for the Sale of Zokinvy® (lonafarnib)Patient Access to Zokinvy® to Continue UninterruptedPALO ALTO, Calif., ...

Peninsula biotech files for Chapter 11 bankruptcy protection

18d ago, source: The Business Journals

Eiger BioPharmaceuticals Inc. filed for Chapter 11 bankruptcy protection, turning its drug approved to treat a rare accelerated aging disease in children into a $26 million "stalking horse ...

Metabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock Nosedives

18d ago, source: Hosted on MSN

Monday, Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) announced that it and its direct subsidiaries have filed voluntary petitions for Chapter 11 protection in the U.S. Bankruptcy Court for the ...

Eiger BioPharmaceuticals Inc (EIGR) Shares Down Despite Recent Market Volatility

10d ago, source: newsheater

The net margin for Eiger BioPharmaceuticals Inc stands at -5.91. The total capital return value is set at -2.14. Equity return is now at value -225.93, with -86.91 for asset returns.

Eiger BioPharmaceuticals, Inc. (72C.F)

1mon ago, source: Yahoo Finance

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and ...

Eiger BioPharmaceuticals Inc EIGR

16d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Metabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock Nosedives

18d ago, source: Benzinga.com

In January, Eiger BioPharmaceuticals and its partner AnGes Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib) for Hutchinson-Gilford ...

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

18d ago, source: ADVFN

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in ...

Eiger BioPharmaceuticals Inc EIGR

26d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...